In a new article on the Practice Update web site, Dr. Howard Scher, an oncologist specializing in treatment of advanced prostate cancer at Memorial Sloan-Kettering Cancer Center in New York, writes about his “top pick” regarding new prostate cancer knowledge from 2013.
Dr Scher discusses the approval of the new α-particle emitting agent known as radium-223 dichloride (Xofigo), our expanding knowledge about the differing subtypes of metastatic, castration-resistant prostate cancer (mCRPC), and our associated expanding understanding of how to select appropriate forms of treatment for men with these differing subtypes of mCRPC.
Editor’s note: Dr. Scher inaccurately refers to radium-223 dichloride by the name “Alpharadin” in his article. Alpharadin was at one point the proposed trade name for radium-223 dichoride; however, the actual trade name finally used here in the USA is Xofigo.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, radium-223, Xofigo |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply